Larimar Therapeutics, Inc. (Nasdaq:LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.
View Top Employees from Larimar Therapeutics Inc.Website | https://larimartx.com |
Revenue | $1 million |
Funding | $23.1 million |
Employees | 40 (38 on RocketReach) |
Founded | 2016 |
Address | Three Bala Plaza East Suite 506, Bala Cynwyd, Pennsylvania 19004, US |
Phone | (844) 511-9056 |
Technologies |
JavaScript,
HTML,
PHP
+29 more
(view full list)
|
Industry | Biotechnology, Drug Discovery, Pharmaceuticals, Science and Engineering, Healthcare, Therapeutics, Health Care |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 54 Companies, NAICS Code 541 Companies, NAICS Code 5417 Companies |
Looking for a particular Larimar Therapeutics Inc. employee's phone or email?
The Larimar Therapeutics Inc. annual revenue was $1 million in 2024.
Mike Celano is the CFO of Larimar Therapeutics Inc..
38 people are employed at Larimar Therapeutics Inc..
Larimar Therapeutics Inc. is based in Bala Cynwyd, Pennsylvania.
The NAICS codes for Larimar Therapeutics Inc. are [54, 541, 5417].
The SIC codes for Larimar Therapeutics Inc. are [28, 283].